-
-
-
-
-
-
-
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
-
-
-
-
-
-
-
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
-
-
-
15,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

